Indian Diagnostic Market Analysis

The Indian diagnostic market has experienced significant growth over the years to become the potential investment area for players looking to venture in the country. Various factors such as rising prevalence of diseases, improving affordability of patients and increasing penetration of health insurance have contributed substantially to spur demand for diagnostic services in the country. With the continuous increase in demand, the market is expected to post around 24% growth in 2010 over the previous year.

According to our new research report “Indian Diagnostic Market Analysis”, the diagnostic market in India is projected to grow at a CAGR of more than 22% between 2010 and 2012. The Indian diagnostics market is comprised of diagnostic instruments, reagents and services. Although the market is currently dominated by local and unorganized players, the organized segment has also reported strong growth to expand its reach in rural and semi urban areas. We expect that high investments in the primary healthcare sector will drive demand for diagnostic services in the country and poor condition of healthcare services in the government sector will result in more revenues to the private sector.

We have found that molecular diagnostics is emerging as one of the fastest growing segments of the diagnostics market. The main reason for such a tremendous growth is the unique ability of molecular diagnostic to treat a wide range of infectious and genetic diseases. Realizing such a huge potential, various companies are pouring investments in this segment. On the other hand, the biochemical testing market is likely to account for the largest share of the diagnostics market.

“Indian Diagnostic Market Analysis” provides comprehensive research, objective analysis and information about important issues of the Indian diagnostic market. It studies the diagnostics market by segmenting it into biochemical testing market, hematology, microbiology, immunology, coagulation, urinalysis, critical care and molecular diagnostics. The report also covers their market size, demand and market segmentation. It also features analysis of future directions, supplemented with facts and figures. In this way, the report serves as a useful guide for diagnostic companies, government officials, consultants and investors who are planning to enter the Indian diagnostic market.
[Studien Infos ausblenden]

1. Analyst View
2. Research Methodology
3. Diagnostic Market Outlook to 2012
3.1 By Diagnosis Techniques
3.1.1 Biochemical Testing
3.1.2 Hematology
3.1.3 Immunology
3.1.4 Microbiology
3.1.5 Coagulation
3.1.6 Critical Care
3.1.7 Urinalysis
3.1.8 Molecular Diagnostics
4. Diseases Prevalence Analysis
5. Cost Analysis
5.1 Affordability Factor
5.2 Health Insurance
6. Current Use of Diagnostic in India
7. Market Analysis
7.1 What Kind of Tests are Needed?
7.2 What Needs to be Tested?
8. Regulatory Environment
9. Key Players
9.1 SRL Ranbaxy
9.2 Dr. Lal PathLabs
9.3 Thyrocare Technologies Limited
9.4 Metropolis Health Services
[Inhaltsverzeichnis ausblenden]

List of Figures:

Figure 3-1: Diagnostics Market (Billion INR), 2007-2012
Figure 3-2: Diagnostics Market by Diagnosis Techniques (%), 2009
Figure 3-3: Forecast for Diagnostics Market by Diagnosis Techniques (%), 2012
Figure 3-4: Molecular Diagnostics Market by Segment (%), 2010
Figure 4-1: Number of Coronary Heart Disease Cases (Million), 2005 & 2015
Figure 4-2: Number of Diabetes Cases (Million), 2010 & 2015
Figure 4-3: New and Total Number of Cancer Patients (‘000)
Figure 5-1: Health Insurance Premium (Billion INR), 2006-07 to 2008-09

List of Tables:

Table 4-1: Prevalence of Overweight & Obesity in Males and Females (%), 2005 & 2015
Table 4-2: Reported Cases of Communicable Diseases (2008)
Table 6-1: Growth in Infectious Diseases Diagnostic Market (2004-2008)
Table 6-2: Growth in Hormones Diagnostic Market (2004-2008)
Table 6-3: Growth in Blood Grouping Reagents Diagnostic Market (2004-2008)
Table 6-4: Growth in Pregnancy Diagnostic Market (2004-2008)
Table 6-5: Growth in Cancer Markers Diagnostic Market (2004-2008)
Table 9-1: SRL Ranbaxy - Strengths and Weaknesses
Table 9-2: Dr. Lal PathLabs - Strengths and Weaknesses
Table 9-3: Thyrocare Technologies Limited - Strengths and Weaknesses
Table 9-4: Metropolis Health Services - Strengths and Weaknesses
[Tabellenverzeichnis ausblenden]